(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Flow Cytometry Market: Global Forecast to 2034" has been added to ResearchAndMarkets.com's offering. The global flow cytometry market is projected to reach USD 10.57 billion by 2034, up from USD 5.56 billion in 2026, expanding at a CAGR of 8.4% during the forecast period. Market growth is supported by rising adoption across immunology, oncology, hematology, drug discovery, cell and gene therapy, and clinical diagnostics.
Conventional flow cytometry, spectral flow cytometry, imaging/hybrid flow cytometry, and bead-based flow cytometry are increasingly used to analyze cell phenotype, viability, apoptosis, cell cycle, intracellular proteins, cytokines, and other functional characteristics. These technologies support cancer diagnostics, autoimmune disease assessment, stem cell research, in vitro toxicity testing, cell sorting, vaccine manufacturing, CGT manufacturing, and biologics production.
Demand is also increasing for high-parameter analyzers, spectral systems, complex antibody-dye conjugates, multiplex assays, and automated data analysis solutions. Pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinical testing laboratories, and CROs & CDMOs are expanding their use of these products. Recurring purchases of antibodies, assays & kits, controls, calibration reagents, sheath fluids, and related consumables provide an additional source of sustained market revenue.
Market expansion may be constrained by the high cost of advanced instruments, complex multicolor panel design, shortages of skilled operators, reagent standardization requirements, and challenges associated with interpreting high-dimensional flow cytometry data.
Bead-based flow cytometry to record the highest CAGR
The bead-based flow cytometry segment is expected to post the highest CAGR during the forecast period. Growth is being driven by increased adoption of multiplex assays for the simultaneous detection and quantification of multiple analytes from limited sample volumes. Bead-based platforms are widely used for cytokine profiling, biomarker analysis, immunoassays, and drug discovery studies, particularly in high-throughput testing environments. Demand for scalable, efficient, and multiplexed analytical workflows across pharmaceutical, biotechnology, and research laboratories will continue to support this segment.
Reagents & consumables maintain the largest market share
Reagents & consumables account for the largest share of the flow cytometry market because they are required repeatedly in routine laboratory workflows. Key products include unconjugated antibodies, antibody-dye conjugates, phenotyping assays & kits, cytokine detection assays & kits, multiplex assays & kits, apoptosis and cell viability assays, buffers, controls, calibration reagents, and sheath fluids. Frequent use in immunophenotyping, cytokine detection, apoptosis analysis, cell viability testing, and other cellular studies reinforces the segment's leading position.
US market expected to expand at the highest CAGR
The US flow cytometry market is projected to grow at the highest CAGR, supported by the presence of major manufacturers, pharmaceutical and biotechnology companies, advanced research infrastructure, and broad adoption of sophisticated cell analysis technologies. Increasing use in oncology, immunology, hematology, drug discovery, cell & gene therapy, and clinical diagnostics is accelerating demand for cell analyzers, cell sorters, spectral flow cytometry systems, multiplex assays, antibody-dye conjugates, and advanced data analysis platforms.
Research coverage
The report analyzes the flow cytometry market by product, technology, detection modality, application, end user, service type, and region. Product coverage includes reagents & consumables, instruments, software, and accessories. Instruments are evaluated across cell analyzers and cell sorters, including high-plex/high-parameter, standard benchtop/mid-parameter, compact/low-parameter, high-range, mid-range, and low-range systems.
Application analysis covers research, clinical, pharmaceutical & biotechnology, and industrial uses. Research applications include drug discovery, stem cell research, in vitro toxicity testing, immunology, cell sorting, apoptosis, cell cycle analysis, cell viability, and cell counting. Clinical applications include cancer diagnostics, hematology, autoimmune diseases, and organ transplantation. Service coverage includes immunophenotyping, cell sorting, assay development, and other specialized services. Regional analysis encompasses North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
Primary research profile
By Respondent: Supply Side (70%) and Demand Side (30%) By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%) By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Competitive landscape
Key companies offering flow cytometry products and services include BD, Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Sony Corporation, Miltenyi Biotec, Enzo Biochem Inc., Sysmex Corporation, Cytek Biosciences, BIOMERIEUX, Cytonome/ST LLC, Sartorius AG, Union Biometrica, Inc., Takara Bio Inc., Revvity, Charles River Laboratories, The Jackson Laboratory, Apogee Flow Systems Ltd., Stratedigm, Inc, Nova Biomedical, On-chip Biotechnologies Co., Ltd. Corporation, Precision Cell Systems, CytoBuoy, CUSABIO TECHNOLOGY LLC, De Novo Software, Altasciences, RayBiotech, Inc., and KCAS Bio.
The report evaluates company profiles, product portfolios, market shares, growth strategies, product launches, acquisitions, investments, and other recent developments. It also examines emerging startups and competitive activity across the flow cytometry industry ecosystem.
Key benefits
The report provides revenue estimates for the overall market and its subsegments, helping established companies and new entrants assess growth opportunities and develop effective go-to-market strategies. It offers analysis of major drivers, including oncology applications, high-parameter and spectral flow cytometry adoption, and cell and gene therapy development. It also assesses restraints and challenges such as instrument costs and reagent development complexity, alongside opportunities in clinical diagnostics, biopharmaceutical quality control, automated workflows, and AI-enabled flow cytometry.
Additional insights cover product innovation, attractive regional markets, untapped geographies, investment activity, market diversification, and competitive positioning. These findings can support strategic planning, product development, partnership decisions, and expansion initiatives across the global flow cytometry market.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment